- Home
- CCCC vs INFU Comparison
CCCC vs INFU Comparison
Compare CCCC & INFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCCC | INFU |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.1M | 196.1M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CCCC | INFU |
|---|---|---|
| Price | $2.91 | $10.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $12.20 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 2.4M | 80.8K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.45 | ★ 181.82 |
| EPS | N/A | ★ 0.31 |
| Revenue | $35,947,000.00 | ★ $143,436,000.00 |
| Revenue This Year | N/A | $3.20 |
| Revenue Next Year | N/A | $7.31 |
| P/E Ratio | ★ N/A | $33.00 |
| Revenue Growth | 1.02 | ★ 6.36 |
| 52 Week Low | $1.20 | $4.66 |
| 52 Week High | $3.82 | $11.04 |
Technical Indicators
Market Signals| Indicator | CCCC | INFU |
|---|---|---|
| Relative Strength Index (RSI) | 55.72 | 68.90 |
| Support Level | $2.30 | $8.52 |
| Resistance Level | $3.82 | $10.84 |
| Average True Range (ATR) | 0.23 | 0.36 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 82.64 | 96.22 |
Price Performance
Historical ComparisonAbout CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.